CYP11A1
Basic information
Region (hg38): 15:74337759-74367646
Previous symbols: [ "CYP11A" ]
Links
Phenotypes
GenCC
Source:
- Congenital adrenal insuffiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency (Strong), mode of inheritance: AR
- Congenital adrenal insuffiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency (Supportive), mode of inheritance: AD
- inherited isolated adrenal insufficiency due to partial CYP11A1 deficiency (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Adrenal insufficiency, congenital, with 46,XY sex reversal, partial or complete | AD/AR | Endocrine; Oncologic; Genitourinary | Presentation of classic enzymatic deficiency involves adrenal failure and salt wasting in infancy, which can be treatable; Nonclassic forms may present later with some retained adrenal function and abnormal sexual development; Surgical interventions may decrease the risk of gonadal tumors | Endocrine; Oncologic; Genitourinary | 11502818; 12161514; 15507506; 16705068; 18182448; 21159840 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (12 variants)
- Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency (4 variants)
- Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (1 variants)
- CYP11A1-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP11A1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 115 | 117 | ||||
missense | 40 | 55 | ||||
nonsense | 9 | |||||
start loss | 0 | |||||
frameshift | 5 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 2 | 24 | 26 | |||
non coding | 65 | 15 | 82 | |||
Total | 15 | 11 | 42 | 185 | 18 |
Highest pathogenic variant AF is 0.0000658
Variants in CYP11A1
This is a list of pathogenic ClinVar variants found in the CYP11A1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
15-74337977-G-A | not specified | Uncertain significance (Aug 02, 2024) | ||
15-74337984-T-C | Likely benign (Mar 25, 2023) | |||
15-74337996-A-G | Likely benign (Jan 19, 2024) | |||
15-74337999-G-T | Likely benign (Sep 08, 2023) | |||
15-74338005-G-A | Likely benign (Feb 16, 2023) | |||
15-74338019-T-C | Inborn genetic diseases | Uncertain significance (Jun 01, 2022) | ||
15-74338020-G-A | Likely benign (Sep 04, 2023) | |||
15-74338027-T-G | Uncertain significance (Apr 12, 2022) | |||
15-74338044-G-A | Likely benign (Aug 16, 2023) | |||
15-74338065-G-A | Likely benign (Jan 04, 2024) | |||
15-74338074-T-C | Likely benign (Oct 27, 2023) | |||
15-74338077-G-T | Likely benign (Oct 17, 2023) | |||
15-74338083-A-G | Likely benign (Oct 11, 2023) | |||
15-74338113-G-C | Likely benign (Aug 14, 2023) | |||
15-74338118-T-C | Likely benign (Jan 04, 2024) | |||
15-74338119-G-A | Likely benign (Dec 17, 2023) | |||
15-74338119-G-T | Likely benign (Sep 15, 2023) | |||
15-74338282-T-C | Benign (Aug 08, 2018) | |||
15-74338552-T-C | Likely benign (Aug 08, 2023) | |||
15-74338556-C-T | Likely benign (Jun 11, 2023) | |||
15-74338557-C-G | Likely benign (Aug 05, 2023) | |||
15-74338574-G-A | Likely benign (Sep 21, 2023) | |||
15-74338577-G-A | Likely benign (Oct 14, 2023) | |||
15-74338580-G-A | Likely benign (Nov 17, 2023) | |||
15-74338586-G-A | Likely benign (Oct 25, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CYP11A1 | protein_coding | protein_coding | ENST00000268053 | 9 | 29982 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
5.49e-7 | 0.967 | 125709 | 0 | 39 | 125748 | 0.000155 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.769 | 277 | 315 | 0.878 | 0.0000199 | 3431 |
Missense in Polyphen | 94 | 120.64 | 0.77917 | 1323 | ||
Synonymous | 0.635 | 118 | 127 | 0.928 | 0.00000797 | 1036 |
Loss of Function | 2.01 | 14 | 24.8 | 0.564 | 0.00000151 | 253 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000275 | 0.000275 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000211 | 0.000202 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone, the precursor of most steroid hormones. {ECO:0000269|PubMed:21636783}.;
- Disease
- DISEASE: Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR) [MIM:613743]: A rare disorder that can present as acute adrenal insufficiency in infancy or childhood. ACTH and plasma renin activity are elevated and adrenal steroids are inappropriately low or absent; the 46,XY patients have female external genitalia, sometimes with clitoromegaly. The phenotypic spectrum ranges from prematurity, complete underandrogenization, and severe early-onset adrenal failure to term birth with clitoromegaly and later-onset adrenal failure. Patients with congenital adrenal insufficiency do not manifest the massive adrenal enlargement typical of congenital lipoid adrenal hyperplasia. {ECO:0000269|PubMed:11502818, ECO:0000269|PubMed:12161514, ECO:0000269|PubMed:16705068, ECO:0000269|PubMed:18182448, ECO:0000269|PubMed:19116240}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Cortisol synthesis and secretion - Homo sapiens (human);Aldosterone synthesis and secretion - Homo sapiens (human);Cushing,s syndrome - Homo sapiens (human);Steroid hormone biosynthesis - Homo sapiens (human);Ovarian steroidogenesis - Homo sapiens (human);Steroidogenesis;Apparent mineralocorticoid excess syndrome;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);Corticosterone methyl oxidase I deficiency (CMO I);Corticosterone methyl oxidase II deficiency - CMO II;Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase Deficiency;Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency;Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;17-alpha-hydroxylase deficiency (CYP17);11-beta-hydroxylase deficiency (CYP11B1);Corticotropin-releasing hormone signaling pathway;Glucocorticoid and Mineralcorticoid Metabolism;WikiPathways Academy- draw-compartment;Oxidation by Cytochrome P450;Metapathway biotransformation Phase I and II;Prostaglandin Synthesis and Regulation;Phase I - Functionalization of compounds;Metabolism of lipids;Endogenous sterols;Cytochrome P450 - arranged by substrate type;Biological oxidations;Metabolism;Pregnenolone biosynthesis;Metabolism of steroid hormones;Metabolism of steroids;C21-steroid hormone biosynthesis and metabolism;pregnenolone biosynthesis;superpathway of steroid hormone biosynthesis;Steroid hormones
(Consensus)
Recessive Scores
- pRec
- 0.140
Intolerance Scores
- loftool
- 0.589
- rvis_EVS
- 0.02
- rvis_percentile_EVS
- 55.61
Haploinsufficiency Scores
- pHI
- 0.308
- hipred
- N
- hipred_score
- 0.261
- ghis
- 0.392
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.990
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cyp11a1
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; immune system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); endocrine/exocrine gland phenotype; muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype;
Zebrafish Information Network
- Gene name
- cyp11a2
- Affected structure
- head
- Phenotype tag
- abnormal
- Phenotype quality
- decreased size
Gene ontology
- Biological process
- C21-steroid hormone biosynthetic process;glucocorticoid biosynthetic process;cholesterol metabolic process;sterol metabolic process;cortisol metabolic process;vitamin D metabolic process;oxidation-reduction process;cellular response to peptide hormone stimulus
- Cellular component
- mitochondrion;mitochondrial inner membrane;mitochondrial matrix
- Molecular function
- iron ion binding;protein binding;cholesterol monooxygenase (side-chain-cleaving) activity;heme binding